http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Jan 2026 07:32:02 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html <p>Bernstein analyst Susannah Ludwig says the recent pullback in European medtech stocks could offer investors a chance to buy into 2026 growth, though caution remains over potential value traps.</p><p>The analyst commented: "A host of headwinds in 2025 including consumer weakness, China regulatory pressures, tariffs, and FX have led many companies in our coverage universe to trade near 10year valuation lows. With a few exceptions, 2025 was a “terrible, horrible, no good, very bad” year for EU Medtech.</p><p>So does this weakness represent a buying opportunity or is it simply a value trap? For long-term investors, we see attractive opportunities to invest http://www.streetinsider.com/Analyst+Comments/Bernstein+on+EU+Medtech%3A+%27A+Buying+Opportunity+or+Is+It+Simply+a+Value+Trap%3F%27/25840681.html Tue, 13 Jan 2026 07:32:02 -0400 ALC AMBBY AMFPY CZMWY DSORF ERFSF GNGBY GNNDY GRRHY PHG SAUHY SDMHF SEMHF SNN SONVY SRTGY TECNF WILYY http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863 http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863 http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863 http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863 http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Press+Releases/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863 http://www.streetinsider.com/Business+Wire/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Business+Wire/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863 http://www.streetinsider.com/Business+Wire/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html <p class="bwalignc"> <b>Company demonstrates highest level of information protection assurance</b> </p> <p> MINNEAPOLIS--(BUSINESS WIRE)-- <b>Amplifon Hearing Health Care</b>, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities. </p><p> The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes <b>have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk.</b> </p><p> <i>“HITRUST certification is globally recognized as validation that information security and<b> </b>privacy controls are effective and compliant with various regulations. HITRUST certification is<b> </b>considered the gold standard because http://www.streetinsider.com/Business+Wire/Amplifon+Hearing+Health+Care+Achieves+HITRUST+r2+Certification/23911657.html Thu, 31 Oct 2024 17:03:00 -0400 A.38960210 AMFPY AMP O.00528920 O.01299863